NCT00550875View on ClinicalTrials.gov

Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Allergic Rhinoconjunctivitis
Interventions
BIOLOGICAL

Grass pollen allergenic extract (L. perenne-C. dactylon )

Sublingual. 2 drops/daily 1000 DPP/ml 2 years

BIOLOGICAL

Grass pollen allergenic extract (L. perenne-C. dactylon )

Sublingual. 2 drops/daily 10000 DPP/ml 2 years

BIOLOGICAL

placebo

Sublingual. 2 drops/daily 2 years

Trial Locations (1)

7700

Allergy Unit, UCT Lung Institute, Mowbray

Sponsors
All Listed Sponsors
lead

Laboratorios Leti, S.L.

INDUSTRY

NCT00550875 - Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis | Biotech Hunter | Biotech Hunter